900530-64-5 Usage
General Description
Ethyl 5-iodothiazole-4-carboxylate is a chemical compound with the molecular formula C7H6INOS. It is a derivative of thiazole, a heterocyclic compound containing a five-membered ring with sulfur and nitrogen atoms. This specific compound is characterized by the presence of an ethyl group, a carboxylate group, and an iodine atom attached to the thiazole ring. It is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and agrochemicals due to its unique structural and functional properties. Additionally, its iodine functionality makes it potentially useful as a tracer in radiolabeling and imaging studies. Overall, ethyl 5-iodothiazole-4-carboxylate is a versatile compound with diverse potential applications in the fields of chemistry and medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 900530-64-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,0,5,3 and 0 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 900530-64:
(8*9)+(7*0)+(6*0)+(5*5)+(4*3)+(3*0)+(2*6)+(1*4)=125
125 % 10 = 5
So 900530-64-5 is a valid CAS Registry Number.
900530-64-5Relevant articles and documents
IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
-
, (2013/11/18)
The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
2-Thioethenyl substituted carbapenem derivatives
-
Page/Page column 15, (2010/11/25)
[Objective] An objective of the present invention is to provide compounds that are effective against various resistant bacteria which cause current clinical problems, for example, pneumococci including penicillin resistant Streptococcus pneumoneae (PRSP),
